Objective: The present study sought to determine changes in plasma levels of catecholamine metabolites and serum levels of brain-derived neurotorophic factor (BDNF) among smokers with schizophrenia who were treated wi...Objective: The present study sought to determine changes in plasma levels of catecholamine metabolites and serum levels of brain-derived neurotorophic factor (BDNF) among smokers with schizophrenia who were treated with varenicline. Methods: We compared plasma homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) levels and serum BDNF levels across 4 groups, divided as follows: smokers with schizophrenia (S-Sc), nonsmokers with schizophrenia (NS-Sc), smokers who were otherwise healthy (S-HC) and nonsmokers who were otherwise healthy (NS-HC). In addition, we also examined plasma HVA and MHPG levels and serum BDNF levels prior to study initiation (T0) and 8 weeks after varenicline treatment (T8) in the S-Sc and S-HC groups. Results: Plasma HVA levels in the S-Sc group at T0 were significantly higher than in the NS-Sc, S-HC and NS-HC groups at the same time point (S-Sc at T0;7.6 ± 1.6 ng/mL, NS-Sc;4.8 ± 1.0 ng/mL, S-HC;4.3 ± 0.9 ng/mL, NS-HC;3.4 ± 1.4 ng/mL, p < 0.0001). Plasma MHPG levels in the S-Sc group at T0 were significantly higher than in the NS-Sc and S-HC groups;in addition, plasma MHPG levels in the NS-HC group were significantly higher than in the S-HC group (S-Sc at T0;5.2 ± 0.7 ng/mL, NS-Sc;2.8 ± 1.2 ng/mL, S-HC;1.9 ± 0.8 ng/mL, NS-HC;3.6 ± 1.3 ng/mL, p < 0.0002). Serum BDNF levels did not differ between the S-Sc and NS-Sc groups. In contrast, no difference in plasma HVA levels, plasma MHPG levels or serum BDNF levels was observed between T0 and T8. Conclusions: In conclusion, plasma levels of HVA and MHPG in the S-Sc group were significantly higher than in the NS-Sc group. Serum BDNF levels did not differ between the S-Sc and NS-Sc groups. Plasma HVA and MHPG levels and serum BDNF levels did not change after treatment with varenicline.展开更多
Background: Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by both motor and non-motor symptoms. Bladder dysfunction is the common non-motor symptom of PD, most often presenting with ...Background: Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by both motor and non-motor symptoms. Bladder dysfunction is the common non-motor symptom of PD, most often presenting with detrusor overactivity (DO). Treatment of DO is currently limited, poorly tolerated and sometimes ineffective. Bladder responses are not only mediated by muscarinic cholinergic receptors (mAChR) but also by nicotinic cholinergic receptors (nAChR). However, nicotinic receptor subtypes and functions in the bladder are not clearly identified. Purpose: This study aimed at investigating the effect of varenicline, an alpha7 full agonist and alpha4beta2/alpha3 partial agonist, on detrusor strips in rat PD model induced by substantia nigra injection of 6-hydroxydopamine. Method: The detrusor activity was studied in an isolated organ bath system. Results: In PD group, the detrusor activity was increased, whereas varenicline decreased the DO. Conclusion: Alpha7 nAChR agonists may have therapeutic potential in treatment of bladder overactivity in PD.展开更多
Background: Varenicline, which is derived from the cytisine compound, is used to assess in smoking cessation. Sleep driving (SD) is often classified as a variant of somnambulism. Although, somnambulism has been report...Background: Varenicline, which is derived from the cytisine compound, is used to assess in smoking cessation. Sleep driving (SD) is often classified as a variant of somnambulism. Although, somnambulism has been reported as a side effect of varenicline, varenicline-induced sleep driving (VISD) has not been reported. Case Report: A 56-year-old man with a history of 35 pack year smoking who presented for smoking cessation counseling. Treatment with varenicline was initiated. In the following night, the patient drove to a shopping center and woke up in his car. Varenicline was discontinued. SD has not been reported in the following nights. In a repeated attempt to stop smoking, treatment with varenicline was resumed by the patient. SD reoccurred in the following night. Varenicline was discontinued indefinitely, and SD has not been reported.展开更多
Pharmacotherapies for tobacco cessation are efficacious and recommended during quit attempts.Racial/ethnic minorities in the United States are less likely to use medication-based aids for tobacco cessation,despite gre...Pharmacotherapies for tobacco cessation are efficacious and recommended during quit attempts.Racial/ethnic minorities in the United States are less likely to use medication-based aids for tobacco cessation,despite greater difficulty achieving long-term abstinence.The reasons for this include,among others,provider-and patient-level considerations.Primary care clinicians play an important role in encouraging racial/ethnic minority tobacco users to use cessation pharmacotherapy.To better understand pharmacotherapy use,we conducted a narrative review of patient-lev-el factors that may determine uptake and adherence.This review indicates that social and cultural factors impact pharmacotherapy use,including health care experiences,beliefs,perceptions,and norms.The proportion of individuals using pharmacotherapy during quit attempts and adhering to the full course of treatment may be enhanced with greater attention to the ethnocultural concerns of these groups.Culturally appropriate assessment and brief advice delivered by primary care providers could yield significant benefits in population health.Recommendations for treating racial/ethnic tobacco users with pharmacotherapy for cessation are offered.展开更多
文摘Objective: The present study sought to determine changes in plasma levels of catecholamine metabolites and serum levels of brain-derived neurotorophic factor (BDNF) among smokers with schizophrenia who were treated with varenicline. Methods: We compared plasma homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) levels and serum BDNF levels across 4 groups, divided as follows: smokers with schizophrenia (S-Sc), nonsmokers with schizophrenia (NS-Sc), smokers who were otherwise healthy (S-HC) and nonsmokers who were otherwise healthy (NS-HC). In addition, we also examined plasma HVA and MHPG levels and serum BDNF levels prior to study initiation (T0) and 8 weeks after varenicline treatment (T8) in the S-Sc and S-HC groups. Results: Plasma HVA levels in the S-Sc group at T0 were significantly higher than in the NS-Sc, S-HC and NS-HC groups at the same time point (S-Sc at T0;7.6 ± 1.6 ng/mL, NS-Sc;4.8 ± 1.0 ng/mL, S-HC;4.3 ± 0.9 ng/mL, NS-HC;3.4 ± 1.4 ng/mL, p < 0.0001). Plasma MHPG levels in the S-Sc group at T0 were significantly higher than in the NS-Sc and S-HC groups;in addition, plasma MHPG levels in the NS-HC group were significantly higher than in the S-HC group (S-Sc at T0;5.2 ± 0.7 ng/mL, NS-Sc;2.8 ± 1.2 ng/mL, S-HC;1.9 ± 0.8 ng/mL, NS-HC;3.6 ± 1.3 ng/mL, p < 0.0002). Serum BDNF levels did not differ between the S-Sc and NS-Sc groups. In contrast, no difference in plasma HVA levels, plasma MHPG levels or serum BDNF levels was observed between T0 and T8. Conclusions: In conclusion, plasma levels of HVA and MHPG in the S-Sc group were significantly higher than in the NS-Sc group. Serum BDNF levels did not differ between the S-Sc and NS-Sc groups. Plasma HVA and MHPG levels and serum BDNF levels did not change after treatment with varenicline.
文摘Background: Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by both motor and non-motor symptoms. Bladder dysfunction is the common non-motor symptom of PD, most often presenting with detrusor overactivity (DO). Treatment of DO is currently limited, poorly tolerated and sometimes ineffective. Bladder responses are not only mediated by muscarinic cholinergic receptors (mAChR) but also by nicotinic cholinergic receptors (nAChR). However, nicotinic receptor subtypes and functions in the bladder are not clearly identified. Purpose: This study aimed at investigating the effect of varenicline, an alpha7 full agonist and alpha4beta2/alpha3 partial agonist, on detrusor strips in rat PD model induced by substantia nigra injection of 6-hydroxydopamine. Method: The detrusor activity was studied in an isolated organ bath system. Results: In PD group, the detrusor activity was increased, whereas varenicline decreased the DO. Conclusion: Alpha7 nAChR agonists may have therapeutic potential in treatment of bladder overactivity in PD.
文摘Background: Varenicline, which is derived from the cytisine compound, is used to assess in smoking cessation. Sleep driving (SD) is often classified as a variant of somnambulism. Although, somnambulism has been reported as a side effect of varenicline, varenicline-induced sleep driving (VISD) has not been reported. Case Report: A 56-year-old man with a history of 35 pack year smoking who presented for smoking cessation counseling. Treatment with varenicline was initiated. In the following night, the patient drove to a shopping center and woke up in his car. Varenicline was discontinued. SD has not been reported in the following nights. In a repeated attempt to stop smoking, treatment with varenicline was resumed by the patient. SD reoccurred in the following night. Varenicline was discontinued indefinitely, and SD has not been reported.
文摘Pharmacotherapies for tobacco cessation are efficacious and recommended during quit attempts.Racial/ethnic minorities in the United States are less likely to use medication-based aids for tobacco cessation,despite greater difficulty achieving long-term abstinence.The reasons for this include,among others,provider-and patient-level considerations.Primary care clinicians play an important role in encouraging racial/ethnic minority tobacco users to use cessation pharmacotherapy.To better understand pharmacotherapy use,we conducted a narrative review of patient-lev-el factors that may determine uptake and adherence.This review indicates that social and cultural factors impact pharmacotherapy use,including health care experiences,beliefs,perceptions,and norms.The proportion of individuals using pharmacotherapy during quit attempts and adhering to the full course of treatment may be enhanced with greater attention to the ethnocultural concerns of these groups.Culturally appropriate assessment and brief advice delivered by primary care providers could yield significant benefits in population health.Recommendations for treating racial/ethnic tobacco users with pharmacotherapy for cessation are offered.
